- General Drug Summary
- Description
- Adrenergic beta-agonist used to control premature labor. [PubChem]
- Also Known As
- Ritodrina [INN-Spanish]; Ritodrine Hcl; Ritodrine Hydrochloride; Ritodrinium [INN-Latin]
- Categories
- Sympathomimetic
- Structure
- Summary In Neonatal Jaundice
-
1 record(s) for Ritodrine Effective in Inducing Remission in Neonatal Jaundice.
- PMID
- Drug Name
- Efficacy
- Evidence
- 10725475
- Ritodrine
- Effective in Inducing Remission
- Randomized Controlled Trial
- Summary
- Associated with a higher incidence of neonatal jaundice when treated with preterm labor compared with nifedipine.
- Neonatal effects of nifedipine and ritodrine for preterm labor. Obstetrics and gynecology, 2000 Apr [Go to PubMed]
- We compared nifedipine and ritodrine for treatment of preterm labor with respect to neonatal outcome.
We conducted an open randomized multicenter study of neonatal outcome in 185 women who received either oral nifedipine (n = 95) or intravenous (IV) ritodrine (n = 90) for treatment of preterm labor. Secondary outcome measures included neonatal mortality and morbidity, especially neonatal intensive care unit (NICU) admission, respiratory distress syndrome (RDS), and intracranial bleeding.
There were no significant differences in umbilical artery pH values and Apgar scores between groups. Nifedipine was associated with lower admission rates to the NICU (49% versus 66%; odds ratio 0. 51, confidence interval 0.28, 0.93) compared with ritodrine, and lower incidences of RDS (21% versus 37%; 0.46, 0.24, 0.89), intracranial bleeding (18% versus 31%; 0.48, 0.24, 0.96), and neonatal jaundice (52% versus 67%; 0.53, 0.29, 0.97). Logistic regression analysis showed that even after correction for gestational age at birth, newborn risk of RDS, intracranial bleeding, or neonatal jaundice was significantly lower in the nifedipine group than the ritodrine group.
Nifedipine for treatment of preterm labor was associated with a lower incidence of neonatal morbidity than ritodrine. That difference appeared to be partly because of the higher tocolytic efficacy of nifedipine and partly because of an intrinsic beneficial effect of nifedipine, or the lack of harmful effects when compared with ritodrine.
-
2 record(s) for Ritodrine NA in Neonatal Jaundice.
- PMID
- Drug Name
- Efficacy
- Evidence
- Summary
- the potential for RH to exacerbate Neonatal jaundice is minimal
- The effect of ritodrine hydrochloride on bilirubin production in neonatal rats. Pediatric pharmacology (New York, N.Y.), 1986 [Go to PubMed]
- The effect of ritodrine hydrochloride (RH) on bilirubin metabolism in newborn Wistar rats was studied. Wistar rat pups were given two 35-mg/kg injections of RH, and total bilirubin formation (TBF) was determined from the whole body excretion rate of carbon monoxide (VeCO). Early labeled bilirubin formation (ELB), plasma bilirubin levels, and hepatic heme oxygenase (HO) activity were also determined. We found significant increases in TBF, ELB, and HO in the RH-treated animals over the control animals. These increases, however, were small, considering the high doses of RH administered. Our findings suggest that at clinically administered doses, the potential for RH to exacerbate neonatal jaundice is minimal.
- 3921037
- Ritodrine
- NA
- Clinical Trial
- Summary
- no deleterious effects on neonates
- Physiologic and biochemical effects of ritodrine therapy on the mother and perinate. American journal of perinatology, 1985 Jan [Go to PubMed]
- The materno-fetal and neonatal effects of ritodrine were studied in 37 women treated for premature labor with intravenous (i.v.) ritodrine. Marked cardiovascular, respiratory, and biochemical side effects of therapy were seen in the mothers and tachycardia was noted in the fetuses. The neonates of 18 women in whom ritodrine successfully postponed delivery were delivered with good Apgar scores and their admission vital signs and nursery courses were benign. Ritodrine failed to delay delivery more than a week in 19 mothers. There were no differences between their newborns and 20 control neonates in admission vital signs, blood gases, blood chemistries, complete blood counts, platelet counts, peak bilirubin, or duration of oxygen therapy. This study revealed no deleterious effects on neonates delivered after maternal ritodrine therapy despite significant maternal and fetal effects.
-
2 record(s) for Ritodrine Adverse Event in Neonatal Jaundice.
- PMID
- Drug Name
- Efficacy
- Evidence
- 6624790
- Ritodrine
- Adverse Event
- Clinical Trial
- Summary
- May lead icterogenic effect in infants.
- Neonatal outcome after treatment with ritodrine: a controlled study. American journal of obstetrics and gynecology, 1983 Oct 1 [Go to PubMed]
- Neonatal condition was assessed in a group of 82 infants born at term after maternal treatment with ritodrine for an average of 28.5 days, and compared with that in a matched control group of infants. No statistically significant differences were found in umbilical pH, Apgar scores, head circumference, and neurological condition. Although the difference was not statistically significant, doubt remains as to a possible icterogenic effect of ritodrine.
- 1687895
- Ritodrine
- Adverse Event
- Clinical Trial
- Summary
- Ritodrine may contribute to producing Neonatal jaundice.
- [Effect of some drugs on physiological icterus in the newborn]. Minerva ginecologica, 1991 Dec [Go to PubMed]
- The Authors have correlated neonatal jaundice with the administration of oxytocin and prifinium bromide to the mother either alone or in association during labour. The percentage of neonatal jaundice in women treated with ritodrine hydrochloride during the second and third trimester of pregnancy was also calculated. A total of 1.101 deliveries were taken into consideration between January 1984 and June 1986. Thirty-three patients were treated with oxytocin alone; 444 patients with oxytocin and prifinium bromide; 81 patients with ritodrine hydrochloride during the second and third trimesters of pregnancy, and 192 patients were untreated. This study indicates that all drugs may contribute to producing neonatal jaundice, as shown in the graphs, and drugs during labour should be used with extreme caution and be limited in quantity and period.
-
1 record(s) for Ritodrine Not Effective to Patients in Neonatal Jaundice.
- PMID
- Drug Name
- Efficacy
- Evidence
- 8368029
- Ritodrine
- Not Effective to Patients
- System Review
- Summary
- agents that stimulate uterine motility (oxytocin) as well as drugs that inhibit uterine motility (ritodrine) may have an icterogenic effect. no practical consequences arise except in such cases where additional risk factors may increase the danger of bilirubin encephalopathies in jaundiced infants
- [Do drugs in pregnancy modify neonatal jaundice?]. Zentralblatt für Gynäkologie, 1993 [Go to PubMed]
- An increased incidence of neonatal jaundice has been observed in babies born to mothers who were treated with different drugs before or during delivery. In this review literature data on such drugs are collected which are under suspicion to produce increased levels of bilirubin in the newborn infant. Despite numerous attempts to show significant effects of these drugs on neonatal hyperbilirubinaemia most of them give contradictory results. Nevertheless, agents that stimulate uterine motility (oxytocin) as well as drugs that inhibit uterine motility (ritodrine) may have an icterogenic effect. Possible mechanisms of their actions are described. Thus, even if there is some association between drugs given prenatally and jaundice developing postnatally, no practical consequences arise except in such cases where additional risk factors may increase the danger of bilirubin encephalopathies in jaundiced infants.